Mammalian Process Development
GTP Bioways is a CDMO with strong expertise in process development. Our team has long-standing experience in developing mammalian processes for standard mAbs as well as for challenging antibody formats and proteins.
For 20 years, our team has successfully been developing mammalian processes for a wide variety of biotherapeutics
including monoclonal antibodies, engineered antibodies, immunocytokines, antibody fragments and Fc- fusion proteins
Customised mammalian upstream bioprocess development
Our highly experienced USP team has successfully developed mammalian processes for the production of standard mAbs as well as of challenging antibody formats and proteins.
Our experience across a diversity of CHO and HEK cell lines – either developed in-house or transferred from a third party – allows us to develop cell culture processes on short timelines. From media development to fed-batch process optimisation, we have the know-how to deliver highly productive, robust, and scalable upstream processes for a seamless transfer to GMP manufacturing.
Expert downstream process development services
Our scientists regard each protein as a unique challenge and have the agility to customise downstream processes to each specific case.
To shorten the time to clinic for mAbs, our process development approach is based on the fine-tuning of our optimised downstream platform to your specific antibody candidate.
For other proteins, our team is used to developing purification schemes from scratch, optimising each downstream unit operation to obtain an efficient, robust, and cost-effective process. When classic technologies are not applicable, we bring innovation into the process, with manufacturability always in mind.